A review of the International Early Recommendations for Departments Organization and Cancer Management Priorities during the Global COVID-19 Pandemic. Applicability in Low- and Middle-Income Countries
Journal
European Journal of Cancer
Date Issued
2020-06
Author(s)
Belkacemi, Yazid
Grellier, Noemie
Ghith, Sahar
Debbi, Kamel
Coraggio, Gabriele
Bounedjar, Adda
Samlali, Redouane
Tsoutsou, Pauletta G.
Ozsahin, Mahmut
Chauvet, Marie-Pierre
Turkan, Sedat
Boussen, Hamouda
Kuten, Abraham
Tesanovic, Dusanka
Errihani, Hassan
Benna, Farouk
Bouzid, Kamel
Idbaih, Ahmed
Mokhtari, Karima
Popovic, Lazar
Spano, Jean-Philippe
Lotz, Jean-Pierre
Cherif, Aziz
To, Hahn
Kovcin, Vladimir
Arsovski, Oliver
Beslija, Semir
Dzodic, Radan
Markovic, Ivan
Vasovic, Suzana
Stamatovic, Liljana
Radosavljevic, Davorin
Radulovic, Sinisa
Vrbanec, Damir
Sahraoui, Souha
Vasev, Nino
Risteski, Milan
Freixa, Salvador Villà
Krengli, Marco
Radosevic, Nina
Mustacchi, Giorgio
Filipovic, Mladen
Kerrou, Khaldoun
Taghian, Alphonse G.
Todorovic, Vladimir
Geara, Fady
Gligorov, Joseph
DOI
10.1016/j.ejca.2020.05.015
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus
that has never been identified in humans before. COVID-19 caused at the time of
writing of this article, 2.5 million cases of infections in 193 countries with 165,000
deaths, including two-third in Europe. In this context, Oncology Departments of the
affected countries had to adapt quickly their health system care and establish new
organizations and priorities. Thus, numerous recommendations and therapeutic
options have been reported to optimize therapy delivery to patients with chronic
disease and cancer.
Obviously, while these cancer care recommendations are immediately applicable in
Europe, they may not be applicable in certain emerging and low and middle income
countries (LMICs). In this review we aimed to summarize these international guidelines
according to cancer types, making a synthesis for daily practice to protect patients,
staff and tailor anti-cancer therapy delivery taking into account patients/tumor criteria
and tools availability. Thus, we will discuss their applicability in the LMICs with different
organizations, limited means and different constraints
that has never been identified in humans before. COVID-19 caused at the time of
writing of this article, 2.5 million cases of infections in 193 countries with 165,000
deaths, including two-third in Europe. In this context, Oncology Departments of the
affected countries had to adapt quickly their health system care and establish new
organizations and priorities. Thus, numerous recommendations and therapeutic
options have been reported to optimize therapy delivery to patients with chronic
disease and cancer.
Obviously, while these cancer care recommendations are immediately applicable in
Europe, they may not be applicable in certain emerging and low and middle income
countries (LMICs). In this review we aimed to summarize these international guidelines
according to cancer types, making a synthesis for daily practice to protect patients,
staff and tailor anti-cancer therapy delivery taking into account patients/tumor criteria
and tools availability. Thus, we will discuss their applicability in the LMICs with different
organizations, limited means and different constraints
Subjects